MEDARTIS HLDG AG SF-,20

Medartis reports H1 2026 sales up 30.7% to CHF 160.8m with 17% organic growth; adjusted EBITDA rose to CHF 28.8m and adjusted net profit returned to positive at CHF 7m. The company raised its full-year guidance for organic sales growth to 17–19% and lifted the target for KeriMedical-TOUCH cases in the US to 1,800. High investments led to negative free cash flow of CHF -10m, but management expects a marked improvement in 2027/2028. The share rose 2.73% to $90.3 after the figures and profitability metrics improved significantly. » Więcej na de.investing.com

Medartis reports group revenue of CHF 146.3m for H2 2025 and organic full-year growth of 15.7%, Core-EBITDA for H2 at CHF 26.8m and an annual margin of 18.4%. Operating free cash flow fell to CHF 9.3m after higher investments in production facilities; CAPEX was 9.6% of revenue. EMEA drove growth at 18.0%, while North America slowed to 13.4% due to sales optimizations and the replacement of a major distribution partner; five new partners are expected to fill the gap within 12 months. Medartis acquires CADskills and expects for 2026 organic core revenue growth of 16–18%, a Core-EBITDA margin in the high teens, and revenue of around CHF 322–328m with EBITDA of around CHF 52–59m, taking into account currency effects and M&A. » Więcej na de.investing.com

Three years ago Medartis’s share price was CHF 68.60; the closing price on Feb. 24, 2026 was CHF 92.00. An investment of CHF 10,000 three years ago would today be worth CHF 13,411.08, a gain of 34.11%. Medartis most recently had a market capitalization of about CHF 1.13 billion. Calculation does not take stock splits or dividends into account. » Więcej na finanzen.net